Actemra* (Tocilizumab) — Medicare Part D spending
Genentech, Inc.* · Rank #315 by total Part D spend · CMS data year 2023
Medicare Part D spent $135,711,700 on Actemra* (Tocilizumab) in 2023, the #315 drug by total Part D spending out of 3,598 drugs. That worked out to about $1,074.35 per dosage unit, $3,999 per claim and $29,696 per beneficiary, across 33,939 claims for 4,570 beneficiaries. Average spending per dosage unit rose +0.5% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Actemra* (Tocilizumab) spending at a glance (2023)
| Metric | Actemra* (Tocilizumab) |
|---|---|
| Total Part D spending (2023) | $135,711,700 |
| Total spending (2022) | $127,758,479 |
| Year-over-year change in total spending | +6.2% |
| Average spending per dosage unit (2023) | $1,074.35 |
| Change in spend per dosage unit (YoY) | +0.5% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +1.4% |
| Average spending per claim (2023) | $3,999 |
| Average spending per beneficiary (2023) | $29,696 |
| Total claims (2023) | 33,939 |
| Beneficiaries (2023) | 4,570 |
| Total dosage units (2023) | 263,213 |
| Manufacturer(s) | Genentech, Inc.* |
| National rank by total spend (of 3,598 drugs) | #315 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $127,758,479 | $135,711,700 | +6.2% |
| Avg spend per dosage unit | $1,069.34 | $1,074.35 | +0.5% |
| Avg spend per claim | $3,796 | $3,999 | — |
| Avg spend per beneficiary | $26,153 | $29,696 | — |
| Total claims | 33,653 | 33,939 | — |
| Beneficiaries | 4,885 | 4,570 | — |
How Actemra* compares with nearby drugs
Drugs with total Part D spending closest to Actemra* (Tocilizumab):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Actemra* (Tocilizumab) (this drug, #315) | $135,711,700 | $1,074.35 | +0.5% |
| Allopurinol (#313) | $136,919,933 | $0.19 | -0.8% |
| Glyxambi (Empagliflozin/Linagliptin) (#314) | $136,590,648 | $20.66 | +4.7% |
| Pennsaid (Diclofenac Sodium) (#316) | $134,792,075 | $23.87 | +1.5% |
| Buspirone HCl (#317) | $134,026,927 | $0.20 | +1.8% |
| Epinephrine (#318) | $133,365,359 | $124.71 | -6.8% |
Frequently asked questions
How much does Medicare Part D spend on Actemra*?
Medicare Part D spent $135,711,700 on Actemra* (Tocilizumab) in 2023 (the latest CMS data year), across 33,939 claims for 4,570 beneficiaries. That ranks #315 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Actemra*?
In 2023, the weighted average Medicare Part D spending per dosage unit for Actemra* (Tocilizumab) was $1,074.35. Compared with 2022 it rose +0.5%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Actemra*?
CMS attributes Actemra* (Tocilizumab) to Genentech, Inc.* in the 2023 Part D spending file. Average spending per claim was $3,999 and per beneficiary $29,696.
Is the Actemra* figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20